MWNA
ARIA

Marshall Wace North America’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Marshall Wace North America’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-29,282
Closed -$539K – 905
2013
Q3 		$539K Buy
+29,282
New +$569K 0.02% 435

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Marshall Wace North America's ARIA Position: Q4 2013 in Review

Marshall Wace North America sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2013, closing a stake of 29,282 shares — an estimated $539K sold.

Marshall Wace North America first reported a position in ARIA in Q3 2013 and held it in 1 quarter. The position peaked at $539K in Q3 2013. 166 funds tracked by Wall St. Rank hold ARIA as of Q4 2013.

  • Marshall Wace North America reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Marshall Wace North America sold 29,282 Ariad Pharmaceuticals Inc shares in Q4 2013, an estimated $539K.
  • Marshall Wace North America first reported a position in Ariad Pharmaceuticals Inc in Q3 2013 and held it in 1 quarter.
  • Marshall Wace North America's Ariad Pharmaceuticals Inc position peaked at $539K in Q3 2013.
  • 166 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2013.

Based on Marshall Wace North America's 13F filing for Q4 2013, filed 14 Feb 2014.